Using ctDNA to monitor treatment in young Hodgkin lymphoma patients
Part of Cancer clinical trials.
This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classical Hodgkin lymphoma.
- You are under 25 years old.
- You are enrolled in a social security plan.
- You have not had chemotherapy or radiation for another cancer before.
- You have not received treatment for Hodgkin lymphoma except possibly a short course of steroids.
- You do not have nodular lymphocyte predominant Hodgkin lymphoma (a different type).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
This study looks at whether measuring a DNA fragment in the blood (called ctDNA) can help predict how well radiotherapy works for head and neck cancer. It may help doctors better tailor treatment for patients with stage III or IV disease.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This study looks at whether a blood test that checks for tiny pieces of tumor DNA (called ctDNA) can help predict how Hodgkin lymphoma will progress. It is for adults who have just been diagnosed with classical Hodgkin lymphoma.
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.